Table 2.
Clinical Characteristics of the Sample
|
Characteristic | |
|
Psychiatric Diagnoses, n (%) | |
| Attention Deficit Hyperactivity Disorder |
96 (87) |
| Disruptive Behavior Disorder |
100 (91) |
| Anxiety Disorder |
36 (33) |
| Tic Disorder |
24 (22) |
| Depressive Disorder |
12 (11) |
| Pervasive Developmental Disorder |
14 (13) |
| Psychotic Disorder |
1 (1) |
|
Pharmacotherapy | |
| Risperidone Dose, mg/d |
1.4 (±1.1) |
| Risperidone Dose, mg/kg/d |
0.03 (±0.02) |
| Age at Start of Risperidone, yrs |
9.1 (±2.8) |
| Treatment Duration, yrs |
2.5 (±1.7) |
| Psychostimulants, n (%) |
78 (71) |
| Psychostimulants Dose, mg/d a |
59.2 (±28.6) |
| Psychostimulants Dose, mg/kg/d a |
1.35 (±0.70) |
| Psychostimulants Treatment Duration, yrs |
4.8 (±2.7) |
| SSRIs, n (%) |
55 (50) |
| Fluoxetine |
21 (19) |
| Sertraline |
16 (15) |
| Citalopram/Escitalopram |
18 (16) |
| SSRI Dose, unit per day b |
1.30 (±0.83) |
| SSRI Treatment Duration, yrs |
2.6 (±2.1) |
| α2-agonists, n (%) | 35 (32) |